NBIX Stock Analysis: Buy, Sell, or Hold?
NBIX - Neurocrine Biosciences Inc
$174.26
6.49 (3.87%)
▲
5d:
+6.14%
30d:
+12.54%
90d:
+31.46%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 29, 2026
25d
Get Alerted When NBIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NBIX shows positive signals but monitor for confirmation. Market pricing in 0.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: NBIX shows positive signals but monitor for confirmation. Market pricing in 0.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$329.40
Based on 13.9% avg growth
INTRINSIC VALUE TODAY
$204.53
14.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NBIX is currently trading at $174.26, which is considered extended relative to its 30-day fair value range of $156.80 to $165.31. The stock's valuation (Forward PE: 13.8) is in line with its historical norms (13.8). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NBIX is in a strong uptrend. The price is approaching resistance at $174.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: NBIX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $195.99 (+12.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBIX is in a strong uptrend. The price is approaching resistance at $174.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: NBIX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $195.99 (+12.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$156.80 -
$165.31
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BEARISH: Price extended above range (+5.4% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading below Wall St target ($195.99)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$156.80 -
$165.31
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$156.31
Resistance Level
$174.38
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.83
Wall Street Target
$195.99
(+12.5%)
Revenue Growth (YoY)
42.2%
Earnings Growth (YoY)
2310.5%
Profit Margin
21.6%
Valuation Premium vs History
+0.2% premium
PE vs Historical
13.8 vs 13.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$174.61
(+0%)
2-Year Target
$174.96
(+0%)
3-Year Target
$175.31
(+1%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
PE COMPRESSION
$174.88
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 23.7%)
$519.16
(+198%)
Base:
(SPY PE: 13.8, Growth: 23.7%)
$329.75
(+89%)
Bear:
(PE: 11.8, Growth: 23.7%)
$280.29
(+61%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 25.81 | Current EPS (TTM): $6.50
Bull Case
$357.64
(+105%)
Analyst growth 93.8%, PE expands to 28.4
Base Case
$325.13
(+87%)
Market implied 93.8%, PE stable at 25.8
Bear Case
$114.08
(-35%)
Severe decline -20.0%, PE contracts to 21.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 3:48 PM ET
Data refreshes hourly during market hours. Next update: 4:48 PM
Data refreshes hourly during market hours. Next update: 4:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kyle Gano
SELL
36400 shares
2026-01-16
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
Advanced NBIX Option Strategies
Professional options setups generated by AI based on today's NBIX price and gamma walls.
